Key result
Antihypertensive medications showed similar patterns of beneficial effects on Alzheimer's disease pathways in animal studies, though methodological limitations prevent comprehensive conclusions.
Why the study?
Do antihypertensive medications improve cognitive function and reduce Alzheimer's disease pathology in animal models and human mechanistic studies?
Do antihypertensive medications improve cognitive function and reduce Alzheimer's disease pathology in animal models and human mechanistic studies?
Mechanistic and animal studies suggest antihypertensive medications may beneficially impact Alzheimer's disease pathways, but methodological heterogeneity limits definitive conclusions.
Answers are grounded in this paper and cite their sources.
Does not support repurposing antihypertensives for Alzheimer's prevention; leaves open translation of animal findings to human trials.
PURPOSE OF REVIEW: There is an established association between hypertension and increased risk of poor cognitive performance and dementia including Alzheimer's disease; however, associations between antihypertensive medications (AHM) and dementia risk are less clear. An increased interest in AHM has resulted in expanding publications; however, none of the recent reviews provide comprehensive review. Our extensive review includes 24 mechanistic animal and human studies published over the last 5 years assessing relationship between AHM and cognitive function. RECENT FINDINGS: All classes of AHM showed similar result patterns in animal studies. The mechanism by which AHM exert their effect was extensively studied by evaluating well-established pathways of AD disease process, including amyloid beta (Aβ), vascular, oxidative stress and inflammation pathways, but only few studies evaluated the blood pressure lowering effect on the AD disease process. Methodological limitations of the studies prevent comprehensive conclusions prior to further work evaluating AHM in animals and larger human observational studies, and selecting those with promising results for future RCTs.
No takes yet. Share an insight, caveat, or question.
Peters et al. (2016) conducted a review in Cognitive impairment and Alzheimer's disease (n=24). Antihypertensive medications vs. Control or comparator group was evaluated on Cognitive function and Alzheimer's disease pathways (amyloid beta, vascular, oxidative stress, inflammation). Antihypertensive medications showed similar patterns of beneficial effects on Alzheimer's disease pathways in animal studies, though methodological limitations prevent comprehensive conclusions.
Synapse has enriched 10 related papers. Consider them for comparative context: